Kiora Pharmaceuticals
KPRX
20 hedge funds and large institutions have $5.44M invested in Kiora Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
18% more funds holding
Funds holding: 17 → 20 (+3)
0.89% less ownership
Funds ownership: 41.26% → 40.37% (-0.89%)
41% less capital invested
Capital invested by funds: $9.16M → $5.44M (-$3.72M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$53.7K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$37.6K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$34.9K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$26.9K |
| 5 |
Millennium Management
New York
|
+$21.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$39K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
-$14K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$12K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5.37K |
KPRX Hedge Fund Activity: Q3 2018 in Review
20 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q3 2018, worth a combined $5.44M — down 41% from $9.16M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new KPRX positions and 3 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Panagora Asset Management, opening a new position worth an estimated $53.7K. The largest seller was Essex Investment Management, exiting entirely with an estimated $39K sold.
- 20 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q3 2018, up from 17 in Q2 2018.
- Funds reported $5.44M of Kiora Pharmaceuticals stock for Q3 2018, down 41% quarter-over-quarter.
- 6 funds opened new Kiora Pharmaceuticals positions in Q3 2018 and 3 closed out, a net change of +3 holders.
- The largest Kiora Pharmaceuticals buyer in Q3 2018 was Panagora Asset Management, an estimated $53.7K added.
- The largest Kiora Pharmaceuticals seller in Q3 2018 was Essex Investment Management, an estimated $39K sold.
Based on aggregated 13F filings for Q3 2018.